The efficacy and toxicity of interferon-α2a (9MU/d) and bleomycin (15 mg every 2 weeks), each combined with zidovudine (2 × 250 mg/d), was compared in a randomized study in 26 men with progressing AIDS-related Kaposi's sarcoma (KS). The median CD4 count was 113/μl. Complete or partial response was achieved in one (8%) of 12 evaluable patients on interferon and in 2 (20%) of 10 patients on bleomycin (P=0.43) during 4.7 and 5.3 months of treatment, respectively. The tolerability was comparable. During extended follow up, survival time was 24 and 13 months in the interferon and bleomycin arm, respectively. In a multivariate Cox regression analysis, CD4 lymphocytes <200/μl (relative risk 3.74; 95% CI: 1.30–10.8) and randomization to interferon (relative risk 0.37; 95% CI: 0.15–0.90) were significantly predictive of mortality. New AIDS-related events occurred more frequently in patients who had received bleomycin. The antiviral activity of interferon-α or the chemotherapy-mediated increase in the risk for opportunistic infections may explain these differences.
GallantJ.E., MooreR.D., RichmanD.D., KerulyJ.Chaisson RE and the Zidovudine Epidemiology Study Group. Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine.Arch Intern Med1994; 154: 566–72.
2.
ChangY., CesarmanE., PessinM.S.Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.Science1994; 266: 1865–9.
3.
HuangY.Q., LiJ.J., KaplanM.H.Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma.Lancet1995; 345: 759–61.
4.
ArmenianH.K., HooverD.R., RubbS.Composite risk score for Kaposi's sarcoma based on a case–control and longitudinal study in the multicenter AIDS Cohort Study (MACS) population.Am J Epidemiol1993; 138: 256–65.
5.
MooreP.S., GaoS.J., DominguezG.Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma.J Virol1996; 70: 549–58.
6.
OrensteinJ.M., AlkanS., BlauveltA.Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy.AIDS1997; 11: F35–F45.
7.
MocroftA., YouleM., GazzardB.Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection.AIDS1996; 10: 1101–5.
8.
GelmannE.P., LongoD., LaneH.C.Combination chemotherapy of disseminated Kaposi's sarcoma in patients with the acquired immune deficiency syndrome.Am J Med1987; 82: 456–62.
9.
GillP.S., RarickM., McCutchanJ.A.Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial.Am J Med1991; 90: 427–33.
10.
SidkyY.A., BordenE.C.Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses.Cancer Res1987; 47: 5155–61.
11.
HoD.D., HartshornK.L., RotaT.R.Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro.Lancet1985; 1: 602–4.
12.
HartshornK.L., NeumeyerD., VogtM.W., SchooleyR.T., HirschM.S.Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro.AIDS Res Hum Retroviruses1987; 3: 125–33.
13.
PlettenbergA., van DykU., StoehrA.Increased risk for opportunistic infections during chemotherapy in HIV-infected patients with Kaposi's sarcoma.Dermatology1997; 194: 234–7.
14.
LaneH.C., KovacsJ.A., FeinbergJ.Antiretroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma.Lancet1988; 2: 1218–22.
15.
de WitR., SchattenkerkJ.K., BoucherC.A., BakkerP.J., VeenhofK.H., DannerS.A.Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma.Lancet1988; 2: 1214–17.
16.
KrownS.E., RealF.X., KrimM.Recombinant leukocyte A interferon in Kaposi's sarcoma.Ann NY Acad Sci1984; 437: 431–8.
17.
VoldberdingP.A., MitsuyasuR.T., GolandoJ.P., SpiegelR.J.Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A).Cancer1987; 59: 620–5.
18.
KovacsJ.A., DeytonL., DaveyR.Combined zidovudine and interferon-alpha therapy in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS).Ann Intern Med1989; 111: 280–7.
19.
KrownS.E., GoldJ.W., NiedzwieckiD.Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS).Ann Intern Med1990; 112: 812–21.
20.
StadlerR., BratzkeB., SchaartF., OrfanosC.E.Long-term combined rIFN-alpha-2a and zidovudine therapy for HIV-associated Kaposi's sarcoma: clinical consequences and side effects.J Invest Dermatol1990; 95: 170S–175S
21.
de WitR., DannerS.A., BakkerP.J., LangeJ.M., Eeftinck SchattenkerkJ.K., VeenhofC.H.Combined zidovudine and interferon-alpha treatment in patients with AIDS-associated Kaposi's sarcoma.J Intern Med1991; 229: 35–40.
22.
FischlM.A., UttamchandaniR.B., ResnickL.A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma.J Acquir Immune Defic Syndr1991; 4: 1–10.
23.
BaumannR., TauberM.G., OpravilM.Combined treatment with zidovudine and lymphoblast interferon-alpha in patients with HIV-related Kaposi's sarcoma.Klin Wochenschr1991; 69: 360–7.
24.
PodzamczerD., BolaoF., ClotetB.Low-dose interferon alpha combined with zidovudine in patients with AIDS-associated Kaposi's sarcoma.J Intern Med1993; 233: 247–53.
25.
FischlM.A., FinkelsteinD.M., HeW.A phase II study of recombinant human interferon-a2a and zidovudine in patients with AIDS-related Kaposi's sarcoma.J Acquir Immune Defic Syndr Hum Retrovirol1996; 11: 379–84.
26.
LassouedK., ClauvelJ.P., KatlamaC., JanierM., PicardC., MatheronS.Treatment of the acquired immune deficiency syndrome-related Kaposi's sarcoma with bleomycin as a single agent.Cancer1990; 66: 1869–72.
de WitR., ReissP., BakkerP.J., LangeJ.M., DannerS.A., VeenhofK.H.Lack of activity of zidovudine in AIDS-associated Kaposi's sarcoma.AIDS1989; 3: 847–50.
29.
World Health Organization.WHO Handbook for Reporting Results of Cancer Treatment.Geneva: Offset Publication no. 1 48, WHO, 1979
30.
KrownS.E., MetrokaC.Wernz JC for the AIDS Clinical Trials Group Oncology Committee. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria.J Clin Oncol1989; 7: 1201–7.
31.
LedergerberB., von OverbeckJ., EggerM., LuthyR. and the Swiss HIV Cohort Study (SHCS). The Swiss HIV cohort study: rationale, organization and selected baseline characteristics.Soz Präventivmed1994; 39: 387–94.
32.
MaussS., JablonowskiH.Efficacy, safety, and tolerance of low-dose, long-term interferon-alpha 2b and zidovudine in early-stage AIDS-associated Kaposi's sarcoma.J Acquir Immune Defic Syndr Hum Retrovirol1995; 10: 157–62.
33.
HartshornK.L., VogtM.W., ChouT.C.Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.Antimicrob Agents Chemother1987; 31: 168–72.
34.
JohnsonV.A., MerrillD.P., VidelerJ.A.Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.J Infect Dis1991; 164: 646–55.
35.
BerglundO., EngmanK., EhrnstA.Combined treatment of symptomatic human immunodeficiency virus type 1 infection with native interferon-alpha and zidovudine.J Infect Dis1991; 163: 710–15.
36.
FrissenP.H.J., van der EndeM.E., Ten NapelC.H.H.Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection.J Infect Dis1994; 169: 1351–5.
37.
FischlM.A., RichmannD.D., SaagM.Safety and antiviral activity of combination therapy with zidovudine, zalcitabine and two doses of interferon-alpha(2a) in patients with HIV: AIDS clinical trials group study 197.J Acquir Immune Defic Syndr Hum Retrovirol1997; 16: 247–53.
38.
Fernandez CruzE., LangJ.M., FrissenJ.Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 × 106/1: results of the Zidon trial.AIDS1995; 9: 1025–35.
39.
HammerS.M., SquiresK.E., HughesM.D.A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less.N Engl J Med1997; 337: 725–33.
40.
BlumL., PelletC., AgbalikaF.Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy.AIDS1997; 11: 1653–5.
41.
StewartS., JablonowskiH., GoebelF.D.Randomised comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma.J Clin Oncol1998; 16: 683–91.
42.
GillP.S., WernzJ., ScaddenD.T.Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.J Clin Oncol1996; 14: 2353–64.
